



VGX Pharmaceuticals Announces Management Promotion

Blue Bell, PA – June 2, 2008 -

VGX Pharmaceuticals, Inc. (VGX) announced today the promotion of Mr. Anthony K. Kim to Senior Director, Strategic Operations. Mr. Kim has been serving as the Director of Investor Relations. Since joining VGX in 2005, Mr. Kim has been responsible for Investor Relations, addressing the needs of our diverse group of investors for both VGX and its affiliate, VGX International, a publicly-traded biopharmaceutical company based in Korea. Mr. Kim has also played an important role in various corporate development operations including management of corporate strategies at VGX International.

"Anthony has been providing invaluable services to many aspects of our business," said Dr. J. Joseph Kim, CEO and President. "This promotion recognizes the important role he has played in our Company's growth and I expect his role and contributions to continue to grow."

Anthony Kim has over 10 years of experience in the securities and banking industry. Prior to joining the Company, he led a financial services company for which he assisted his clients in raising money from high net-worth individuals and financial institutions. Mr. Kim holds a Bachelor's Degree in Economics from the University of Washington.

Cautionary Factors That May Affect Future Results - Materials in this Web site contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, PENNVAX™-B for HIV infection, which is in 2 separate Phase I clinical trials, and VGX-1027 for inflammatory diseases, which is in Phase I clinical trials. In addition, the Company has filed INDs for VGX-3100, a DNA therapeutic vaccine for cervical cancer; VGX-3200, a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia and anemia; and VGX-3400, a DNA preventative vaccine for avian influenza. VGX has established a vertically-integrated DNA Vaccines and Therapies Platform with extensive capabilities including SynCon™ DNA-based product candidates, the CELLECTRA® delivery device, and efficient cGMP plasmid manufacturing facilities. The cGMP facilities are used for VGX's own product supplies and for contract manufacturing. Vertical control over key aspects of product development has enabled the Company to consistently develop multiple product candidates, from bench-to-IND filing, within 1 year. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas
Senior Vice-President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com